Hylenex recombinant (hyaluronidase) injection, 150 USP units/mL, 4x1 mL Single Dose Vials, Rx onl...
FDA Drug Recall #D-0116-2025 - Class II, September 11, 2024
Recall Summary
| Recall Number | D-0116-2025 |
| Classification | Class II - Moderate risk |
| Date Initiated | September 11, 2024 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Mckesson Medical-Surgical Inc. Corporate Office |
| Location | Richmond, VA |
| Product Type | Drugs |
| Quantity | 5 cartons/20 units each carton |
Product Description
Hylenex recombinant (hyaluronidase) injection, 150 USP units/mL, 4x1 mL Single Dose Vials, Rx only, Manufactured for and marketed by Halozyme, Inc., 12390 El Camino Real San Diego California 92130, Distributed by Antares Pharma, Inc., Ewing, NJ NDC 18657-117-04
Reason for Recall
cGMP Deviations: Temperature excursion
Distribution Pattern
Virgina
Lot / Code Information
Serial # 100000831961 100000820688 100000820689 100000820515
Other Recalls from Mckesson Medical-Surgical Inc. Corpor...
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-0400-2025 | Class II | Medroxyprogesterone Acetate Injectable Suspensi... | Apr 25, 2025 |
| D-0401-2025 | Class II | Infuvite Adult, multiple vitamins injection, Ba... | Apr 25, 2025 |
| D-0538-2025 | Class II | PROLIA (denosumab), injection, 60mg/mL, For Sub... | Apr 21, 2025 |
| D-0539-2025 | Class II | EVENITY, (romosozumab -aqqg) injection, 105mg/1... | Apr 21, 2025 |
| D-0540-2025 | Class II | BENLYSTA (belimumab) for injection, 400 mg/20 ... | Apr 21, 2025 |
Frequently Asked Questions
cGMP stands for Current Good Manufacturing Practice, the FDA's regulations governing drug manufacturing quality. A cGMP recall means the company failed to follow required manufacturing standards. This could involve inadequate testing, poor environmental controls, documentation failures, or process deviations. cGMP recalls do not always mean the product is directly harmful, in many cases, quality records are insufficient to confirm the product meets specifications. However, the FDA requires a recall because without proper documentation, product quality cannot be assured. These are often Class II or Class III recalls.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications, even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications, use a drug take-back program.